Walter Rosebrough - STERIS Plc CEO
| STE Stock | USD 200.24 1.23 0.62% |
CEO
Mr. Walter M. Rosebrough, Jr. is President, Chief Executive Officer of the Company. He assumed this role when he joined STERIS in October 2007. Mr. Rosebrough is a Director of Varex Imaging Corporationrationration. since 2007.
| Age | 70 |
| Tenure | 17 years |
| Address | 70 Sir John Rogerson?s Quay, Dublin, Ireland, D02 R296 |
| Phone | 353 1 232 2000 |
| Web | https://www.steris.com |
STERIS Plc Management Efficiency
The company has Return on Asset of 0.0477 % which means that on every $100 spent on assets, it made $0.0477 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0911 %, implying that it generated $0.0911 on every 100 dollars invested. STERIS Plc's management efficiency ratios could be used to measure how well STERIS Plc manages its routine affairs as well as how well it operates its assets and liabilities. As of April 18, 2024, Return On Tangible Assets is expected to decline to 0.02. In addition to that, Return On Capital Employed is expected to decline to 0.03. At present, STERIS Plc's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 216.5 M, whereas Debt To Assets are forecasted to decline to 0.16.Similar Executives
| Found 8 records | CEO Age | ||
| Roger Susi | Iradimed Co | 71 | |
| Gary Maharaj | SurModics | 61 | |
| Thomas Hook | Integer Holdings Corp | 51 | |
| Joseph Dziedzic | Integer Holdings Corp | 56 | |
| Leonard Liptak | ProSomnus Common Stock | 49 | |
| Massimo Calafiore | Orthofix Medical | N/A | |
| Bradley Mason | Orthofix Medical | 63 | |
| Joel Becker | Neuropace | 56 | |
Management Performance
| Return On Equity | 0.0911 | ||||
| Return On Asset | 0.0477 |
STERIS plc Leadership Team
Elected by the shareholders, the STERIS Plc's board of directors comprises two types of representatives: STERIS Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of STERIS. The board's role is to monitor STERIS Plc's management team and ensure that shareholders' interests are well served. STERIS Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, STERIS Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Breeden, Independent Director | ||
| Daniel Carestio, Chief Operating Officer, Senior Vice President, Director | ||
| John Wareham, Independent Chairman of the Board | ||
| J Zangerle, Senior Vice President General Counsel, Secretary | ||
| Julia Madsen, Senior Sciences | ||
| Kevin McMullen, Independent Director | ||
| Gulam Khan, Senior Vice President - Procedural Solutions | ||
| Michael Wood, Independent Director | ||
| Andrew Xilas, Senior Dental | ||
| Julie Winter, Vice Communications | ||
| Jack Wareham, Independent Chairman of the Board | ||
| Michael Tokich, CFO, Principal Accounting Officer, Sr. VP and Treasurer | ||
| Karen Burton, CFO, Chief Accounting Officer, Vice President Controller | ||
| Paul Martin, Independent Director | ||
| John Zangerle, Senior Vice President General Counsel, Secretary | ||
| Michiel Zwaan, Chief Human Resource Officer, Vice President | ||
| Kenneth Kohler, Senior AST | ||
| Adrian Coward, Senior Vice President - Healthcare Specialty Services | ||
| Jacqueline Kosecoff, Independent Director | ||
| Mary Fraser, SVP Officer | ||
| Cynthia Feldmann, Independent Director | ||
| Renato Tamaro, Vice President and Corporate Treasurer | ||
| Nirav Shah, Independent Director | ||
| Mohsen Sohi, Independent Chairman of the Board | ||
| Adam Zangerle, Company Secretary | ||
| Walter Rosebrough, CEO and President Director and Member of Compliance Committee | ||
| Richard Steeves, Independent Director | ||
| Loyal Wilson, Independent Director | ||
| Duncan Nichol, Independent Director | ||
| Christopher Holland, Independent Director | ||
| Bruce Edwards, Director | ||
| Kathleen Bardwell, COO, Senior Vice President | ||
| Sudhir Pahwa, Senior Vice President - Infection Prevention Technologies | ||
| David Lewis, Independent Director | ||
| Cary Majors, Vice President - North America Commercial Operations |
STERIS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is STERIS Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0911 | ||||
| Return On Asset | 0.0477 | ||||
| Profit Margin | 0.10 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 23.21 B | ||||
| Shares Outstanding | 98.81 M | ||||
| Shares Owned By Insiders | 0.27 % | ||||
| Shares Owned By Institutions | 97.96 % | ||||
| Number Of Shares Shorted | 2.68 M | ||||
| Price To Earning | 36.93 X |
Currently Active Assets on Macroaxis
When determining whether STERIS plc is a strong investment it is important to analyze STERIS Plc's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact STERIS Plc's future performance. For an informed investment choice regarding STERIS Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in STERIS plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For information on how to trade STERIS Stock refer to our How to Trade STERIS Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Complementary Tools for STERIS Stock analysis
When running STERIS Plc's price analysis, check to measure STERIS Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy STERIS Plc is operating at the current time. Most of STERIS Plc's value examination focuses on studying past and present price action to predict the probability of STERIS Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move STERIS Plc's price. Additionally, you may evaluate how the addition of STERIS Plc to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is STERIS Plc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of STERIS Plc. If investors know STERIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about STERIS Plc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.145 | Dividend Share 1.98 | Earnings Share 5.69 | Revenue Per Share 54.709 | Quarterly Revenue Growth 0.148 |
The market value of STERIS plc is measured differently than its book value, which is the value of STERIS that is recorded on the company's balance sheet. Investors also form their own opinion of STERIS Plc's value that differs from its market value or its book value, called intrinsic value, which is STERIS Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because STERIS Plc's market value can be influenced by many factors that don't directly affect STERIS Plc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between STERIS Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine if STERIS Plc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, STERIS Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.